Abstract Number: 2650 • 2013 ACR/ARHP Annual Meeting
Silent Ischemic Heart Disease In Patients With Primary Antiphospholipid Syndrome
Background/Purpose: Premature atherosclerosis in PAPS is still a matter of debate Patients and Methods: To determine the prevalence of ischemic heart disease in…Abstract Number: 2654 • 2013 ACR/ARHP Annual Meeting
IgG Antibodies Directed Against Domain I Of ß2-Glycoprotein I Are Significant Predictors Of Thromboembolic Events In Patients With Antiphospholipid Antibodies. A Prospective Cohort Study
AbstractBackground/Purpose : Our objective was to prospectively determine the prognostic significance of laboratory variables regarding thrombotic events during follow-up, including novel assays IgG antibodies directed…Abstract Number: 2550 • 2013 ACR/ARHP Annual Meeting
Predictive Markers Of Preeclampsia During Pregnancy In Patients With Systemic Erithematosus LUPUS and / Or Antiphospholipid Syndrome
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of preeclampsia (PE), which can be confused with lupus nephritis. Our objective was to…Abstract Number: 1735 • 2012 ACR/ARHP Annual Meeting
Independent Validation of the Antiphospholipid Score (aPL-S) for the Diagnosis of Antiphospholipid Syndrome (APS)
Background/Purpose: The so called “antiphospholipid score (aPL-S)” was recently developed and validated (1). This score was shown to be a useful quantitative index for diagnosing…Abstract Number: 1734 • 2012 ACR/ARHP Annual Meeting
Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities
Background/Purpose: The clinical accuracy of testing for antiphospholipid antibody (aPL) both, as individual tests and/or in combination, is still being investigated. We aimed to identify…Abstract Number: 1733 • 2012 ACR/ARHP Annual Meeting
Effect of Hydroxychloroquine (HCQ) On the Annexin A5 Resistance Assay (AnxA5-RA) in Antiphospholipid Antibody (aPL)-Positive Patients: Preliminary Results of an Ongoing Prospective Study
Background/Purpose: One proposed mechanism of aPL-mediated thrombosis is disruption of the AnxA5 shield, allowing initiation of coagulation reactions on phospholipid surfaces. The AnxA5-RA measures the…Abstract Number: 1728 • 2012 ACR/ARHP Annual Meeting
Purified IgG From Antiphospholipid Syndrome Patients with Pregnancy Morbidity Alone Inhibit Trophoblast Migration and Activate a TLR4 MyD88 Independent Pathway
Background/Purpose: Patients with the Antiphospholipid Syndrome (APS) have circulating antiphospholipid antibodies which cause vascular thrombosis (VT) and/or pregnancy morbidity (PM). Previously we have shown that…Abstract Number: 1724 • 2012 ACR/ARHP Annual Meeting
Pandemic Influenza Immunization in Primary Antiphospholipid Syndrome (PAPS): A Trigger to Autoantibody Production?
Background/Purpose: There are scarce data suggesting that pandemic influenza vaccination may induce antiphospholipid (APL) autoantibodies in inflammatory rheumatic diseases, particularly in systemic lupus erythematosus patients.…Abstract Number: 1740 • 2012 ACR/ARHP Annual Meeting
Impairment of Quality of Life in Patients with Antiphospholipid Syndrome
Background/Purpose : Quality of life (QoL) is an important outcome in clinical care especially in patients with chronic disease such as systemic lupus erythematosus (SLE).…Abstract Number: 1737 • 2012 ACR/ARHP Annual Meeting
Diffuse Alveolar Hemorrhage Caused by Primary Antiphospholipid Syndrome
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an uncommon but severe complication of primary antiphospholipid syndrome (APS). The available literature is limited to very few case…Abstract Number: 2404 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus and/or Antiphospholipid Antibody Positive Patients: Two-Year Preliminary Analysis of Diet and Exercise Habits
Background/Purpose: SLE patients have high rate of cardiovascular events due to increased prevalence of traditional cardiovascular disease (CVD)- and other lupus-related thrombosis risk factors. In…Abstract Number: 2460 • 2012 ACR/ARHP Annual Meeting
Dual Antiplatelet Therapy As Prophylaxis of Recurrent Arterial Thrombosis in Patients with antiphospholipid Syndrome
Background/Purpose: Arterial thrombosis (AT) is a major clinicalmanifestation of the antiphospholipid syndrome (APS). A number of studies have evaluated the rate of recurrent thromboembolism, including…Abstract Number: 2459 • 2012 ACR/ARHP Annual Meeting
Efficacy of Aspirin for the Prevention of the First Thrombo-Embolic Events in Patients with Antiphospholipid Antibodies: A Metanalysis of Literature Data
Background/Purpose: Whether aspirin is needed in patients with antiphospholipid antibodies (aPL+) for prevention of a first thrombotic event is controversial. The aim of this metaanalysis…Abstract Number: 2458 • 2012 ACR/ARHP Annual Meeting
The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infarction, and Deep Vein Thrombosis
Background/Purpose: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is an international research network that has been created specifically to design and…Abstract Number: 2456 • 2012 ACR/ARHP Annual Meeting
Pro-Inflammatory and Pro-Thrombotic Markers in Persistently Antiphospholipid Antibody-Positive Patients with/without Systemic Lupus Erythematosus
Background/Purpose: Pro-inflammatory/thrombotic biomarkers (BMR), which are associated with aPL-mediated pathogenic effects in vitro/vivo, are also increased in aPL-positive patients. Here we examined whether those BMR…
- « Previous Page
- 1
- …
- 9
- 10
- 11